Emergent BioSolutions (EBS) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 18.6% versus a loss of 28.7%. Over five years, KMDA leads with a +49.7% price change compared with -86.1% for EBS. Kamada is the larger company by market cap ($455.3 million vs $362.5 million), about 1.3 times the size.
On valuation, Emergent BioSolutions trades at a lower forward P/E (6.8x vs 13.7x for Kamada). Kamada pays a dividend yielding 3.17%, while Emergent BioSolutions does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | KMDA |
|---|---|---|
| Share price | $7.07 | $7.89 |
| Market cap | $362.50M | $455.33M |
| 1-day change | +1.73% | -2.71% |
| YTD return | -42.80% | +11.76% |
| 1-year return | -28.73% | +18.65% |
| 5-year return | -86.05% | +49.72% |
| P/E ratio (TTM) | — | 20.76 |
| Forward P/E | 6.76 | 13.68 |
| EPS (TTM) | $-3.40 | $0.38 |
| Dividend yield | 0.00% | 3.17% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $14.06 | $9.35 |
| 52-week low | $4.36 | $6.55 |
| Distance from 52-week high | -49.72% | -15.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.59% | +71.10% |
| Average volume | 1.16M | 118.76K |
| Shares outstanding | 51.27M | 57.71M |
| Employees | 900 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed EBS by 47.4 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.17% vs 0.00%).
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
EBS vs KMDA FAQ
Which is bigger, Emergent BioSolutions or Kamada?
Kamada (KMDA) is larger, with a market capitalization of $455.33M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or KMDA?
KMDA returned +18.65% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Emergent BioSolutions or Kamada?
Kamada pays a dividend yielding 3.17%, while Emergent BioSolutions does not currently pay a regular dividend.
Are Emergent BioSolutions and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.